KOMBOGLYZE 2.5 mg/1000 mg, film-coated tablet 60 tablets
Active ingredients: Metformin hydrochloride, Saxagliptin hydrochloride, Saxagliptin
Commercialized according to BDPMDispensing in France: Prescription only
Film-coated tablet60 tabletsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- KOMBOGLYZE 2,5 mg/1000 mg, comprimé pelliculé
- Pharmaceutical form
- comprimé pelliculé
- Route of administration
- orale
- Presentation description
- plaquette(s) thermoformée(s) aluminium de 60 comprimé(s)
- Marketing authorisation holder
- ASTRAZENECA AB
- Reimbursement according to BDPM
- 15 %
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 30 Jan 2026
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
68674913CIP72200789CIP133400922007892Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| CHLORHYDRATE DE METFORMINEcomprimé | 1000 mg · un comprimé | SA |
| SAXAGLIPTINEcomprimé | 2,5 mg · un comprimé | FT |
| CHLORHYDRATE DE SAXAGLIPTINEcomprimé | — | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The published catalog does not list other packages of similar medicines.